DPS Group links up with Bilthoven Biologicals
LEIDEN, Netherlands – July 25th, 2019 – The Irish engineering and project management company DPS Group has linked with a Dutch architectural and construction company to design and construct a new future proof laboratory facility for the pharmaceutical group Bilthoven Biologicals (BBIO) in Utrecht, Netherlands. The project marks an important step in Bilthoven Biologics’ strategy to develop affordable vaccines for the world infant population.
For the BBIO project, DPS has formed a partnership with Kuiper Compagnons, a specialist architectural firm serving the life sciences industry and Kropman Contamination Control, one of the main contractors in the Netherlands serving the pharmaceutical industry. DPS will be providing full project management and design services for the new laboratory complex at Bilthoven Biologicals. The new facility will be to GMP, Biosafety Level 3 (BSL3) and GAPIII compliant.
DPS Chief Executive Frank Keogh said: “This is an important project for DPS and underlines our leading role in the life science market in the Netherlands. We see this as a next step in a long successful partnership with Bilthoven Biologicals. In this partnership we will not only deliver a design that meets all requirements but will also ensure that the project is delivered safely, within time and budget.
“We are delighted to establish this partnership with Kuiper Compagnons and Kropman and with the contribution of our partners we are able to offer early cost and schedule certainty for Bilthoven Biologicals.” He added, this is a significant project and reinforces DPS’s reputation in continental Europe as a major player in the design and project management of pharmaceutical and life sciences facilities.
Jan-Eric Zandbergen, CEO Bilthoven Biologics: “We believe that the DPS team offered the best people who share our philosophy and will look after our interests throughout this very important project for Bilthoven.”
About DPS Group
DPS Group is a global engineering, consulting and project management company, serving high-tech industries around the world. DPS delivers services for clients across the complete engineering and construction value chain including feasibility studies, concepts, consulting, architecture, engineering, procurement, construction management, commissioning, qualification and validation; as well as contingent staffing solutions.
DPS applies its extensive process engineering expertise built over 45 years, as well as significant Lean construction experience to assist clients in high-end process sectors such as pharmaceuticals, biotech and semiconductors to deliver manufacturing facilities speedily, safely and cost effectively. What sets the firm apart are the partnerships it builds with clients through a fundamental understanding of their businesses and its own agility, flexibility, original thinking and high-caliber people.
DPS has grown substantially in recent years and now employs more than 1,700 people in 15 offices and on client sites in Ireland, U.K., Netherlands, Belgium, Sweden, Switzerland, Israel, Singapore, and the United States. For more information, visit www.dpsgroupglobal.com.
About Bilthoven Biologics
Bilthoven Biologicals is a biopharmaceutical company which produces Inactivated Polio Vaccines (IPV), Tetanus Vaccines, Diphtheria-Tetanus-Polio Vaccines (DT-PV) and Bacillus Calmette-Guérin (BCG) for the treatment of bladder cancer. We deliver our vaccines to UNICEF, with which we support the World Health Organisation (WHO) to eradicate polio. 50% of the polio vaccines used in the polio eradication programme come from Bilthoven Biologicals. Bilthoven Biologicals has been part of the Cyrus Poonawalla Group since 2012, the world’s largest vaccine producer and employs more than 450 employees in the Netherlands.
www.bbio.nl | www.werkenbijbbio.nl
